Tripodi, B., Carbone, M. G., Matarese, I., Rizzato, R., Della Rocca, F., De Dominicis, F., & Callegari, C. (2025). Effectiveness of pharmacological treatments for adult ADHD on psychiatric comorbidity: A systematic review. Journal of Clinical Medicine, 14(24), 8848. https://doi.org/10.3390/jcm14248848
- This study reviewed research on adult ADHD medications, including methylphenidate, lisdexamfetamine, atomoxetine, and bupropion.
- The strongest and most consistent finding was that ADHD medication improves core ADHD traits, such as attention, impulsivity, and executive functioning.
- The study found no consistent evidence that ADHD medication directly treats other psychiatric diagnoses, including:
- Depression
- Anxiety disorders
- Substance use disorders
- Personality disorder diagnoses
- Across studies, however, ADHD medication often improved emotional dysregulation, such as emotional intensity, reactivity, and impulsive emotional responses.
- Because emotional dysregulation overlaps with many psychiatric diagnoses, some people may experience secondary reductions in distress or symptom severity, even when the diagnosis itself does not change.
- These secondary effects were variable, limited, and not universal.
- The evidence is emerging and mixed, with important limitations including small samples, short follow-up periods, and high variability between studies.
Bottom Line
ADHD medication treats ADHD.It may ease emotional dysregulation.
That can sometimes reduce distress linked to other diagnoses.
It does not reliably treat those diagnoses themselves.
Other Important Findings from This Study
1. Effects varied by subtype and baseline state, not just diagnosis
Several studies showed that outcomes depended on baseline emotional state, not simply diagnostic category.
- For example, anxiety sometimes improved in people with high baseline anxiety but worsened in people with low baseline anxiety when taking stimulants.
- This suggests ADHD medication does not have a uniform emotional effect and must be interpreted contextually, not categorically. (Tripodi et al., 2025)
2. Emotional dysregulation showed more consistent change than mood symptoms
Across diagnoses:
- Emotional reactivity and impulsivity shifted more reliably than depression or anxiety scores.
- This suggests emotional dysregulation may be more responsive to ADHD medication than mood symptoms themselves. (Tripodi et al., 2025)
3. Personality disorder findings were narrow and specific
- Improvements were mainly seen in borderline-related features such as emotional impulsivity and decision-making.
- Evidence came from very small or short-term studies, including an N-of-1 trial.
- The authors explicitly describe this evidence as preliminary, not strong. (Tripodi et al., 2025)
4. Substance use findings showed short-term change, not long-term stability
- Several studies found reduced craving or use during treatment.
- Long-term abstinence and relapse prevention were not reliably demonstrated.
- Medication effects appeared supportive, not sufficient on their own. (Tripodi et al., 2025)
5. ADHD medication sometimes helped functioning without changing diagnosis
Some studies showed:
- Improved quality of life
- Better decision-making
- Improved daily functioning
Even when diagnostic symptom scales did not change significantly.
This reinforces an important distinction:
Function can improve even when diagnoses remain the same.
6. Evidence quality was explicitly rated as limited
- Evidence was classified as preliminary, emerging, or moderate
- No medication–diagnosis pairing reached high-confidence evidence
- Findings should be used cautiously in practice (Tripodi et al., 2025)
One-Sentence Synthesis
ADHD medication reliably improves ADHD traits, often softens emotional dysregulation, may reduce distress or improve functioning in specific areas, but does not consistently treat co-occurring diagnoses—and its effects vary by person, context, and baseline state.